scholarly journals Promising Advances in LINC01116 Related to Cancer

2021 ◽  
Vol 9 ◽  
Author(s):  
Yating Xu ◽  
Xiao Yu ◽  
Menggang Zhang ◽  
Qingyuan Zheng ◽  
Zongzong Sun ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Lung Cancer ◽  
Cancer Colorectal ◽  
Malignant Tumors ◽  
Biological Processes ◽  
Aberrant Expression ◽  
Protein Coding ◽  
Future Studies ◽  
Non Coding Rnas

Long non-coding RNAs (lncRNAs) are RNAs with a length of no less than 200 nucleotides that are not translated into proteins. Accumulating evidence indicates that lncRNAs are pivotal regulators of biological processes in several diseases, particularly in several malignant tumors. Long intergenic non-protein coding RNA 1116 (LINC01116) is a lncRNA, whose aberrant expression is correlated with a variety of cancers, including lung cancer, gastric cancer, colorectal cancer, glioma, and osteosarcoma. LINC01116 plays a crucial role in facilitating cell proliferation, invasion, migration, and apoptosis. In addition, numerous studies have recently suggested that LINC01116 has emerged as a novel biomarker for prognosis and therapy in malignant tumors. Consequently, we summarize the clinical significance of LINC01116 associated with biological processes in various tumors and provide a hopeful orientation to guide clinical treatment of various cancers in future studies.

scholarly journals Long Non-Coding RNAs and Related Molecular Pathways in the Pathogenesis of Epilepsy

2019 ◽  
Vol 20 (19) ◽  
pp. 4898 ◽  
Author(s):  
Villa ◽  
Lavitrano ◽  
Combi
Keyword(s):  
Biological Processes ◽  
Complete Understanding ◽  
Aberrant Expression ◽  
Protein Coding ◽  
Diagnostic Biomarkers ◽  
Functional Roles ◽  
The Central Nervous System ◽  
Non Coding Rnas ◽  
Underlying Mechanisms ◽  
Coding Capacity

Epilepsy represents one of the most common neurological disorders characterized by abnormal electrical activity in the central nervous system (CNS). Recurrent seizures are the cardinal clinical manifestation. Although it has been reported that the underlying pathological processes include inflammation, changes in synaptic strength, apoptosis, and ion channels dysfunction, currently the pathogenesis of epilepsy is not yet completely understood. Long non-coding RNAs (lncRNAs), a class of long transcripts without protein-coding capacity, have emerged as regulatory molecules that are involved in a wide variety of biological processes. A growing number of studies reported that lncRNAs participate in the regulation of pathological processes of epilepsy and they are dysregulated during epileptogenesis. Moreover, an aberrant expression of lncRNAs linked to epilepsy has been observed both in patients and in animal models. In this review, we summarize latest advances concerning the mechanisms of action and the involvement of the most dysregulated lncRNAs in epilepsy. However, the functional roles of lncRNAs in the disease pathogenesis are still to be explored and we are only at the beginning. Additional studies are needed for the complete understanding of the underlying mechanisms and they would result in the use of lncRNAs as diagnostic biomarkers and novel therapeutic targets.

scholarly journals A PILOT CLINICAL TRIAL TO MONITOR RESPONSE TO CHEMOTHERAPY USING THE CA-62 MARKER OF EPITHELIAL CARCINOMAS

2019 ◽  
Vol 18 (5) ◽  
pp. 18-28
Author(s):  
G. G. Khakimova ◽  
Zh. R. Cherkasova ◽  
S. A. Tsurkan ◽  
G. A. Fedchikov ◽  
N. V. Suganov ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Lung Cancer ◽  
Ovarian Cancer ◽  
Cancer Colorectal ◽  
Performance Status ◽  
Small Cell ◽  
Small Cell Lung ◽  
Neuroendocrine Cancer ◽  
Response To Chemotherapy

The objective of the study was to assess the feasibility of using CA -62 marker of epithelial carcinomas for monitoring treatment response and detecting cancer progression or recurrence during chemotherapy.Material and Methods. A 12-month double-blind clinical trial was conducted by two independent groups: clinical oncologists and biochemists, and involved 89 patients with different cancers confirmed by histopathological findings. The other inclusion criteria were: the presence of at least one measurable lesion according to the RECIST criteria, ECOG performance status 0-2 and satisfactory laboratory parameters. The expression of CA -62 cancer marker was measured by immunochemiluminescent assay used for the detection of epithelial carcinomas.Results. The elevated level of CA -62 marker was observed in 76 patients before starting the treatment. After completion chemotherapy, the level of this marker decreased to the normal reference ranges (<4600 U/ml) in 53 % of patients and remained increased in 24 % of patients. Of 24 % of patients with the initial low level of CA -62 marker (1000–4000 U/ml) before treatment, 12 % had no changes in the level of this marker during chemotherapy; however, 5 % of these patients had disease progression and 7 % had stable disease after starting the treatment. In 12 % of patients with an initial low CA -62 level, it increased during chemotherapy, indicating disease progression.Conclusion. The changes in the level of CA -62 marker during chemotherapy in patients with gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer showed a high correlation (76–100 % depending on the tumor site) with the performance status of the patients according to RECIST criteria. The CA -62 marker was shown to be feasible for monitoring gastric cancer, small-cell lung cancer, colorectal cancer, neuroendocrine cancer and ovarian cancer as well as for assessing the response to chemotherapy.

scholarly journals MicroRNAs in colorectal cancer

2019 ◽  
Vol 7 (8) ◽  
pp. 3206
Author(s):  
Jonathan E. Cruz-Escobar ◽  
Alan Isaac Valderrama-Treviño ◽  
Jesús C. Ceballos-Villalva ◽  
Mariana Ramírez-Guerrero ◽  
German E. Mendoza-Barrera ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Target Genes ◽  
Randomized Clinical Trials ◽  
Malignant Tumors ◽  
Aberrant Expression ◽  
Mature Microrna ◽  
Library Studies ◽  
Non Coding Rnas ◽  
Online Library ◽  
Carcinogenic Process

Colorectal cancer (CRC) is the third most common type of cancer worldwide, currently representing the most common gastrointestinal cancer with 13% of all malignant tumors. MicroRNAs (miRNAs) are small non-coding RNAs that repress the translation of target genes. Since their discovery, they have been shown to play an important role in the development of cancer, since they can act as tumor suppressors or oncogenes. A literature review was performed in different databases such as Medline, PubMed, Cochrane, nature, Wolters Kluwer, ScienceDirect, Scopus, SpringerLink, Wiley Online Library. Studies were included from 2003 to 2018. Colorectal cancer presents genetic heterogeneity, because it can develop in different ways, the pathway through which cancer occurs depends on the gene initially altered. The aberrant expression of microRNAs is implicated in the development of colorectal cancer and its progression. Three existing steps in the maturation of the microRNAs have been identified: 1) transcription of the pri-miRNA, 2) cleavage in the nucleus to form the pre-miRNA and 3) a final excision in the cytoplasm to form the mature microRNA. It has been discovered that miRNAs have an impact on cell proliferation, apoptosis, stress response, maintenance of stem cell potency and metabolism, all important factors in the etiology of cancer. The data analyzed in this article highlights the importance of the study of microRNAs in colorectal cancer, however, for the carcinogenic process, progression, therapeutic management and prognosis, more multicenter randomized clinical trials are needed with a detailed analysis.

scholarly journals Analysis of the Onset and Mortality of Common Malignant Tumors Among Registered Residents in Xishan District in 2016

2020 ◽  
Vol 4 (1) ◽  
Author(s):  
Xuejing Xia ◽  
Dazhuo Lu ◽  
Meiqiong Jiang ◽  
Xincai Zhou ◽  
Weilin Zhang
Keyword(s):  
Colorectal Cancer ◽  
Lung Cancer ◽  
Mortality Rate ◽  
Malignant Tumor ◽  
Prevention And Control ◽  
Cancer Colorectal ◽  
Malignant Tumors ◽  
Female Breast Cancer ◽  
Female Breast ◽  
And Control

Objective: To analyse the cancer incidence and mortality in xishan district in 2016, and to provide scientific basis for tumor prevention and control. Methods: The 2016 malignant tumor registration report data in xishan district were collected and analysed, stratified according to gender and age, and the reported incidence of malignant tumor in xishan district was calculated and analysed (all the following incidence rates belong to the reported incidence), gender, age incidence, bid acceptance rate, mortality and other related indicators. Results: The total registered population of malignant tumor in xishan district in 2016 was 540,494 (268 553 males and 271 941 females), and 876 new cases were reported. The incidence rate was 162.07/105, the bid-winning rate was 176.39 /105, the world standard rate was 91.16/105, and the cumulative rate (0-74 years old) was 10.44%. The incidence of malignant tumors in males (159.00/105) was lower than that in females (165.11/105). Incidence increases with age, rises sharply and rapidly around age 40, and declines after reaching a peak at age 75. Lung cancer, colorectal cancer, thyroid cancer and female breast cancer are common malignant tumors in the western mountainous areas. It accounts for about 55% of the total number of new malignant tumors. In 2016, 653 people died of malignant tumors in xishan district. The mortality rate was 120.82/105 (male mortality 151.11/105, female mortality 90.46/105), the bid-winning mortality rate was 43.53/105, and the bid-winning mortality rate was 57.72/105. Lung cancer, liver cancer, colorectal cancer and stomach cancer are the malignant tumors with high mortality, accounting for about 62% of the death. Conclusion: The morbidity and mortality of malignant tumors are relatively high in xishan district, and prevention and control of lung cancer, liver cancer, stomach cancer, colorectal cancer, female breast cancer and thyroid cancer should be emphasized.

scholarly journals A Review on the Carcinogenic Roles of DSCAM-AS1

2021 ◽  
Vol 9 ◽  
Author(s):  
Soudeh Ghafouri-Fard ◽  
Tayyebeh Khoshbakht ◽  
Mohammad Taheri ◽  
Kaveh Ebrahimzadeh
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Antisense Rna ◽  
Breast Tumor ◽  
Cancer Colorectal ◽  
Small Cell ◽  
Small Cell Lung ◽  
Breast Tumor Cells ◽  
Non Coding Rnas

Long non-coding RNAs (lncRNAs) are a group of transcripts with fundamental roles in the carcinogenesis. DSCAM Antisense RNA 1 (DSCAM−AS1) is an example of this group of transcripts which has been firstly identified in an attempt to find differentially expressed transcripts between breast tumor cells and benign breast samples. The pathogenic roles of DSCAM-AS1 have been vastly assessed in breast cancer, yet its roles are not restricted to this type of cancer. Independent studies in non-small cell lung cancer, colorectal cancer, osteosarcoma, hepatocellular carcinoma, melanoma and cervical cancer have validated participation of DSCAM-AS1 in the carcinogenic processes. miR-577, miR-122-5p, miR-204-5p, miR-136, miR−137, miR−382, miR−183, miR−99, miR-3173-5p, miR-874-3p, miR-874-3p, miR-150-5p, miR-2467-3p, miR-216b, miR-384, miR-186-5p, miR-338-3p, miR-877-5p and miR-101 are among miRNAs which interact with DSCAM-AS1. Moreover, this lncRNA has interactions with Wnt/β-catenin pathway. The current study aims at summarization of the results of studies which focused on the assessment of oncogenic role of DSCAM-AS1.

scholarly journals Diagnostic and Prognostic Potential of Circulating Long Non-Coding RNAs in Non Small Cell Lung Cancer

2018 ◽  
Vol 49 (2) ◽  
pp. 816-827 ◽  
Author(s):  
Wei Peng ◽  
Jun Wang ◽  
Bin Shan ◽  
Zhenzi Peng ◽  
Yeping Dong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Protein Function ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Protein Coding ◽  
Cell Lung Carcinoma ◽  
Therapeutic Modalities ◽  
Diagnosis And Prognosis ◽  
Non Coding Rnas

Lung cancer is the leading cause of cancer-related mortality worldwide. Approximately 80% of lung cancer cases are non–small cell lung carcinoma (NSCLC). However current diagnostic and therapeutic modalities against NSCLC are ineffective due to incomplete understanding of molecular pathogenesis of NSCLC. Emerging evidence shows that long non-coding RNAs (lncRNAs) can function as biomarkers for diagnosis and prognosis. LncRNAs can control transcription, translation, and protein function via diverse mechanisms although they lack the protein coding potential. LncRNAs have attracted intense investigations on their roles in cancer. Mounting evidence indicates that lncRNAs are promising biomarkers in diagnosis and prognosis for NSCLC, especially their presence in body fluids. Herein we will review recent advances in the research that explores the diagnostic and prognostic potentials of lncRNAs in NSCLC. We will also discuss emerging evidence that suggested lncRNAs as therapeutic targets in NSCLC.

The Regulatory Role of Both MBNL1 and MBNL1-AS1 in Several Common Cancers

2021 ◽  
Vol 27 ◽  
Author(s):  
Qi Zhang ◽  
Yinxin Wu ◽  
Jinlan Chen ◽  
Yuxuan Cai ◽  
Bei Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Colorectal Cancer ◽  
Gastric Cancer ◽  
Lung Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Rna Splicing ◽  
Metabolic Regulation ◽  
Overall Survival Rate

Background: MBNL1, a protein encoded by q25 gene on chromosome 3, belongs to the tissue-specific RNA metabolic regulation family, which controls RNA splicing.[1]MBNL1 formed in the process of development drive large transcriptomic changes in cell differentiation,[2] it serves as a kind of tumor differentiation inhibitory factor.MBNL1 has a close relationship with cancer, comprehensive analysis, [3]found that breast cancer, leukemia, stomach cancer, esophageal adenocarcinoma, glial cell carcinoma and another common tumor in the cut, and cut in Huntington's disease. But MBNL1 plays a promoting role in cervical cancer, is contradictory in colorectal cancer, It promotes colorectal cancer cell proliferation, On the other hand, it inhibits its metastasis, so it is an important physiological marker in many cancers. When we integrated the role of MBNL1 protein in various tumors, we found that its antisense RNA, MBNL1-AS1, had a good inhibitory effect in several colorectal cancer, non-small cell lung cancer, and gastric cancer. Objective: To elucidate the expression of MBNL1 and MBNL1-AS1 in various tumors, and to search for their physiological markers. Methods: It was searched by the PUMUB system and summarized its expression in various cancers. Results: MBNL1 was down-regulated, leukemia, breast cancer, glioblastoma, gastric cancer, overall survival rate, recurrence, metastasis increased. While the metastasis of colon cancer decreased, proliferation was promoted, and the effect of both was promoted for cervical cancer.MBNL1-AS1 was down-regulated, and the overall survival rate, recurrence, and metastasis of lung cancer, colorectal cancer, and bladder cancer increased. Conclusion: MBNL1 may be an important regulator of cancer, and MBNL1-AS1 is a better tumor suppressor.

scholarly journals Involvement of Long Non-Coding RNAs (lncRNAs) in Tumor Angiogenesis

2020 ◽  
Vol 6 (4) ◽  
pp. 42 ◽  
Author(s):  
Julia Teppan ◽  
Dominik A. Barth ◽  
Felix Prinz ◽  
Katharina Jonas ◽  
Martin Pichler ◽  
...  
Keyword(s):  
Tumor Angiogenesis ◽  
Biological Processes ◽  
Protein Coding ◽  
Diagnostic Biomarkers ◽  
Oncogenic Pathways ◽  
Therapeutic Molecules ◽  
Cancer Types ◽  
Non Coding Rnas ◽  
Effective Use ◽  
To Receive

Long non-coding RNAs (lncRNAs) are defined as non-protein coding transcripts with a minimal length of 200 nucleotides. They are involved in various biological processes such as cell differentiation, apoptosis, as well as in pathophysiological processes. Numerous studies considered that frequently deregulated lncRNAs contribute to all hallmarks of cancer including metastasis, drug resistance, and angiogenesis. Angiogenesis, the formation of new blood vessels, is crucial for a tumor to receive sufficient amounts of nutrients and oxygen and therefore, to grow and exceed in its size over the diameter of 2 mm. In this review, the regulatory mechanisms of lncRNAs are described, which influence tumor angiogenesis by directly or indirectly regulating oncogenic pathways, interacting with other transcripts such as microRNAs (miRNAs) or modulating the tumor microenvironment. Further, angiogenic lncRNAs occurring in several cancer types such as liver, gastrointestinal cancer, or brain tumors are summarized. Growing evidence on the influence of lncRNAs on tumor angiogenesis verified these transcripts as potential predictive or diagnostic biomarkers or therapeutic targets of anti-angiogenesis treatment. However, there are many unsolved questions left which are pointed out in this review, hence driving comprehensive research in this area is necessary to enable an effective use of lncRNAs as either therapeutic molecules or diagnostic targets in cancer.

Sign in / Sign up

Export Citation Format

Share Document